Pura Vida Investments LLC Takes $157,000 Position in Acasti Pharma Inc (ACST)

Pura Vida Investments LLC acquired a new stake in Acasti Pharma Inc (NASDAQ:ACST) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 188,260 shares of the biopharmaceutical company’s stock, valued at approximately $157,000. Pura Vida Investments LLC owned 0.24% of Acasti Pharma as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. K.J. Harrison & Partners Inc acquired a new position in shares of Acasti Pharma in the 4th quarter valued at about $28,000. Geode Capital Management LLC acquired a new position in shares of Acasti Pharma in the 4th quarter valued at about $40,000. Finally, Bank of Montreal Can lifted its holdings in shares of Acasti Pharma by 60.3% in the 4th quarter. Bank of Montreal Can now owns 247,612 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 93,185 shares during the period. 3.47% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently weighed in on ACST shares. Zacks Investment Research raised Acasti Pharma from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Monday, December 17th. ValuEngine cut Acasti Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.

NASDAQ ACST opened at $1.07 on Friday. The stock has a market capitalization of $84.38 million, a P/E ratio of -1.41 and a beta of 1.23. Acasti Pharma Inc has a twelve month low of $0.43 and a twelve month high of $1.80. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 0.06.

Acasti Pharma (NASDAQ:ACST) last released its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. As a group, equities research analysts expect that Acasti Pharma Inc will post -0.36 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Pura Vida Investments LLC Takes $157,000 Position in Acasti Pharma Inc (ACST)” was first reported by PressOracle and is the sole property of of PressOracle. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://pressoracle.com/news/2019/03/17/pura-vida-investments-llc-takes-157000-position-in-acasti-pharma-inc-acst.html.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Recommended Story: How Buying a Call Option Works

Want to see what other hedge funds are holding ACST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acasti Pharma Inc (NASDAQ:ACST).

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.